Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Symbiosis Pharmaceutical Service announced the purchase of new premises in Stirling, Scotland, UK.
read more
Monday, November 20, 2023
The recent merger of Symbio LLC and Dow Development Laboratories LLC with Proinnovera has given rise to Symbio Proinnovera, a dedicated dermatology-focused Contract Research Organization (CRO).
read more
Sygnature Discovery is strengthening its HTS and translational oncology service-offerings by investing £3 million in new instrumentation and equipment.
read more
Sygnature Discovery has appointed Dr. Nick Moore as Senior Director, Business Development, in a newly-created role to promote the
in vivo pharmacology and consultancy services offered by RenaSci.
read more
Thursday, September 10, 2020
Sygnature Discovery has appointed Dr. Andy Mead as Director and Head of Drug Abuse and Substance Use Disorders at its integrated in vivo pharmacology company, RenaSci.
read more
Tuesday, February 24, 2026
Sygnature Discovery, a drug discovery contract research organization (CRO), announced a strategic brand relaunch, including a new website.
read more
Monday, September 25, 2023
Sygnature Discovery and UBE Corporation have begun a collaboration on a Hit-to-Lead program to identify SHP2 degraders.
read more
Wednesday, April 01, 2026
Sygnature Discovery announced the appointment of Susanne Back as Head of In Vivo Pharmacology, further strengthening its bioscience leadership and reinforcing its commitment to delivering high-quality, integrated drug discovery solutions for ...
read more
Wednesday, April 15, 2020
Sygnature Group is supporting the Government’s COVID-19 testing strategy with the loan of a key piece of equipment.
read more
Sygnature Discovery announced a new addition to its leadership team, with the appointment of industry veteran Jade Dagher as General Manager for Canada.
read more
Monday, September 23, 2019
Sygnature Discovery has announced its US office has moved.
read more
Monday, November 11, 2019
Sygnature Discovery has added in-house high-throughput screening to its range of drug discovery services. This is backed up by its new Leadfinder compound library.
read more
Monday, November 06, 2023
Sygnature Discovery has incorporated an Azenta compound management storage system into its capabilities, enabling the storage of customer libraries as well. High-fidelity hit finding is a crucial initial step in successful drug discovery projects, ...
read more
Wednesday, January 19, 2022
In a broad career, Dr Woler has held multiple key roles in the sector, including CEO at Roche France, Executive Chairman for Europe at SmithKline Beecham PLC, and CEO at Cadus Pharmaceutical in the US.
read more
Sygnature Discovery has established a new office presence in South San Francisco’s biotech hub at Oyster Point, where it can better serve current and future clients on the US west coast.
read more